Antiplatelet effect of spironolactone via modulation of cPLA2-mediated thromboxane A2 generation in murine platelets
Sanggu Kim, Preeti Kumari Chaudhary, Seongmo Yang, Soochong Kim · 2026
Read Antiplatelet effect of spironolactone via modulation of cPLA2-mediated thromboxane A2 generation in murine platelets by Sanggu Kim, Preeti Kumari Chaudhary, Seongmo Yang, Soochong Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655564.txt.
Description
Sanggu Kim and co-authors report a 2026 mouse study on a common blood pressure drug, spironolactone, and its surprise effect on platelets. Steroids often raise clot risk, yet this drug's direct action on platelet activation was murky. The team treated mouse platelets with the drug and measured clumping, granule release, and the making of thromboxane A2, a signal that feeds back to boost clotting.
The drug cut the second wave of clumping and the granule release that depends on that feedback signal. It also lowered thromboxane output under two triggers and damped a key enzyme's activation step. In aspirin-treated platelets the effect mostly vanished, which pins the action to the thromboxane path.
Catalog record
| CREATOR | Sanggu Kim, Preeti Kumari Chaudhary, Seongmo Yang, Soochong Kim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |